ALSO NOTED: Inspire files amended NDA; Genetic variations influence Coumadin use; Immunomedics begins Phase III;and much more..

> Inspire Pharmaceuticals is taking another shot at gaining approval for its experimental treatment for dry eye, filing an amended NDA for a drug that has failed two Phase III trials. Story

> Newly discovered genetic variations play a role in determining the right dose of the anti-clotting drug Coumadin. Article

> Immunomedics of Morris Plains, New Jersey, has begun dosing patients in a Phase III trial of its lead drug -- epratuzumab -- for lupus. Release

> Teva Pharmaceutical has received final FDA approval for a generic version of Abbott's antibiotic Biaxin Tablets. Story

> Neurion Pharmaceuticals has won a $500,000 grant from the National Institute of Mental Health. Release

> Chiron and the Multiple Myeloma Research Consortium announced the initiation of a Phase I clinical trial of CHIR-258 in multiple myeloma. Release

And Finally... A variety of cash-strapped states are considering new "botaxes," adding levies on cosmetic procedures. Story

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.